| A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation BW Ramsey, J Davies, NG McElvaney, E Tullis, SC Bell, P Dřevínek, ... New England Journal of Medicine 365 (18), 1663-1672, 2011 | 2514 | 2011 |
| Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation PM Farrell, TB White, CL Ren, SE Hempstead, F Accurso, N Derichs, ... The Journal of pediatrics 181, S4-S15. e1, 2017 | 1031 | 2017 |
| ECFS best practice guidelines: the 2018 revision C Castellani, AJA Duff, SC Bell, HGM Heijerman, A Munck, F Ratjen, ... Journal of cystic fibrosis 17 (2), 153-178, 2018 | 805 | 2018 |
| European cystic fibrosis society standards of care: best practice guidelines AR Smyth, SC Bell, S Bojcin, M Bryon, A Duff, P Flume, N Kashirskaya, ... Journal of cystic fibrosis 13, S23-S42, 2014 | 789 | 2014 |
| US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis RA Floto, KN Olivier, L Saiman, CL Daley, JL Herrmann, JA Nick, ... Thorax 71 (Suppl 1), i1-i22, 2016 | 607 | 2016 |
| Simple pediatric nutritional risk score to identify children at risk of malnutrition I Sermet-Gaudelus, AS Poisson-Salomon, V Colomb, MC Brusset, ... The American journal of clinical nutrition 72 (1), 64-70, 2000 | 527 | 2000 |
| Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial E Kerem, MW Konstan, K De Boeck, FJ Accurso, I Sermet-Gaudelus, ... The Lancet Respiratory Medicine 2 (7), 539-547, 2014 | 387 | 2014 |
| European best practice guidelines for cystic fibrosis neonatal screening C Castellani, KW Southern, K Brownlee, JD Roelse, A Duff, M Farrell, ... Journal of Cystic Fibrosis 8 (3), 153-173, 2009 | 341 | 2009 |
| Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis I Sermet-Gaudelus, KD Boeck, GJ Casimir, F Vermeulen, T Leal, ... American journal of respiratory and critical care medicine 182 (10), 1262-1272, 2010 | 292 | 2010 |
| A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis V WITKO-SARSAT, P LESAVRE, S LOPEZ, G BESSOU, C HIEBLOT, ... Journal of the American Society of Nephrology 10 (6), 1224-1233, 1999 | 292 | 1999 |
| Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients N Degand, E Carbonnelle, B Dauphin, JL Beretti, M Le Bourgeois, ... Journal of clinical microbiology 46 (10), 3361-3367, 2008 | 264 | 2008 |
| Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST) EF McKone, D Borowitz, P Drevinek, M Griese, MW Konstan, ... The lancet Respiratory medicine 2 (11), 902-910, 2014 | 243 | 2014 |
| European cystic fibrosis bone mineralisation guidelines I Sermet-Gaudelus, ML Bianchi, M Garabédian, RM Aris, A Morton, ... Journal of Cystic Fibrosis 10, S16-S23, 2011 | 229 | 2011 |
| Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study CE Lindan, K Mankad, D Ram, LK Kociolek, VM Silvera, N Boddaert, ... The Lancet Child & Adolescent Health 5 (3), 167-177, 2021 | 219 | 2021 |
| In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study I Sermet-Gaudelus, M Renouil, A Fajac, L Bidou, B Parbaille, S Pierrot, ... BMC medicine 5, 1-10, 2007 | 197 | 2007 |
| Mycobacterium abscessus and children with cystic fibrosis I Sermet-Gaudelus, M Le Bourgeois, C Pierre-Audigier, C Offredo, ... Emerging infectious diseases 9 (12), 1587, 2003 | 189 | 2003 |
| Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis C Pierre-Audigier, A Ferroni, I Sermet-Gaudelus, M Le Bourgeois, ... Journal of clinical microbiology 43 (7), 3467-3470, 2005 | 185 | 2005 |
| Impact of COVID-19 on people with cystic fibrosis C Colombo, PR Burgel, S Gartner, S van Koningsbruggen-Rietschel, ... The Lancet Respiratory Medicine 8 (5), e35-e36, 2020 | 177 | 2020 |
| Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators IM Pranke, A Hatton, J Simonin, JP Jais, F Le Pimpec-Barthes, A Carsin, ... Scientific reports 7 (1), 7375, 2017 | 155 | 2017 |
| A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis R Cosgriff, S Ahern, SC Bell, K Brownlee, PR Burgel, C Byrnes, H Corvol, ... Journal of cystic fibrosis 19 (3), 355-358, 2020 | 154 | 2020 |